These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 26011514

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 3. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 4. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
    Pollock RF, Muduma G.
    Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Dec; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR.
    Arzneimittelforschung; 2010 Dec; 60(6a):386-98. PubMed ID: 20648930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C, FERGI Study Group.
    Clin Gastroenterol Hepatol; 2013 Mar; 11(3):269-77. PubMed ID: 23078888
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Retrospective cohort study comparing the adverse reactions and efficacy of intravenous iron polymaltose with ferric carboxymaltose for iron deficiency anemia.
    Gilmartin CE, Hoang T, Cutts BA, Leung L.
    Int J Gynaecol Obstet; 2018 Jun; 141(3):315-320. PubMed ID: 29498039
    [Abstract] [Full Text] [Related]

  • 15. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L, Pensabene L, El-Khouly S, Chadokufa S, McCartney S, Saliakellis E, Kiparissi F, Borrelli O.
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [Abstract] [Full Text] [Related]

  • 16. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [Abstract] [Full Text] [Related]

  • 17. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.
    Bager P, Dahlerup JF.
    J Crohns Colitis; 2010 Oct; 4(4):427-30. PubMed ID: 21122539
    [Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
    Ikuta K, Ito H, Takahashi K, Masaki S, Terauchi M, Suzuki Y.
    Int J Hematol; 2019 Jan 28; 109(1):50-58. PubMed ID: 30194568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.